 Home > Active Ingredient News > Drugs Articles > Shamrock Bio's Hong Kong stock IPO, with a market value of 15.5 billion Hong Kong dollars

Shamrock Bio's Hong Kong stock IPO, with a market value of 15.5 billion Hong Kong dollars

 Last Update: 2021-11-14
 Source: Internet
 Author: User

Tags

biotechnology fields

tumor microenvironment review

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 4, 2021, the issue price of Clover Biology was determined to be HK$13.

Clover's IPO raised a total of 1.

Cornerstone investors to subscribe for a total of 8052 million shares, the subscription amount of HK $ 1.

Board members include biological clover founder Peng Liang, CEO Liang fruit, and Wang Xiaodong, Wu Xiaobin and so on

In February of this year, after clover biology completed a $230 million Series C financing, its valuation has reached $930 million, and its valuation has risen six times within one year

Shamrock Bio was established in 2008, the founder is Dr.

CUSBEA: Forty years of ups and downs

Three symmetry is a form of action evolved in many biological processes, such as TNF receptor superfamily proteins

On September 22, 2021, Clover Biology announced the Phase 2/3 clinical results of the new crown vaccine SCB-2019

The clover biological new crown vaccine is designed with a trimeric protein, which is more in line with the natural conformation of the new crown virus S protein

After the global offering, Liang Peng holds 17.

Summarize

At the beginning of its establishment, Shamrock Biosciences exclusively completed the angel round of financing by Tianhe Biotechnology, also in Chengdu.

Armstrong technology full carding series

GPRC5D target points are all sorted out;

CD40 targets are all sorted out ;

CD47 targets are all sorted out ;

Full combing of CD47 targets ; Full combing of CD47 targets

Complement targeted drug technology is comprehensively sorted out;

Complement drugs: an important direction of ophthalmology treatment;

Claudin 6 targets are all sorted out;

Claudin 18.

The target is cold and warm, the industry knows it;

China's macromolecular new drug research and development pattern;

The "me too" that was bombarded;

A century of adjuvant ;

A century of insulin legend;

CUSBEA: Forty years of wind and rain;

The anxiety of China's new drug research and development;

R&D competition among Chinese biomedical companies;

China's dual anti-competitive landscape;

China's ADC competition pattern;

China's dual antibody technology is fully combed;

China's ADC technology is fully combed;

Ambrx technology is fully combed;

Vir Biotech technology is fully combed;

Immune-Onc technology is fully combed;

A complete review of Kai Tu's biotechnology;

Tongyi medical technology is comprehensively sorted out;

Biocytometer technology is fully combed;

Tengshengbo medicine technology is fully combed;

Chuangsheng Group's technology is comprehensively combed;

Yongtai Biotechnology is fully combed;

Comprehensive review of China's antibody technology ;

China's antibody technology is fully combed

Deqi medical technology is fully combed;

Hebo medical technology is fully combed ;

Rongchang Biotechnology is fully combed ;

Zai Lab has comprehensively sorted out the technology of Zai Lab ;

WuXi Biotech's comprehensive review ;

Jikai gene technology is fully combed;

CStone Pharmaceutical's technology is fully combed ;

BeiGene's technology is fully combed ;

BeiGene technology comprehensive review 2nd edition;

Cinda Biotechnology comprehensively sorted out ;

Zhongshan Kangfang's technology is fully combed ;

Fuhong Henlius technology is fully combed ;

Junshi Biotechnology is fully combed ;

Jiahe Biotechnology comprehensively sorted out ;

Zhidao Biotechnology comprehensively sorted out ;

Doyle Biotechnology comprehensively sorted out ;

Shangjian Biotechnology is fully combed;

Corning Jerry's technology is fully combed ;

；

Kewang medical technology is comprehensively sorted out ;

；

Comprehensive analysis of Anmai Biotechnology ;

Lijin Biotechnology is comprehensively sorted out ;

Kangqiao Capital's technology is fully combed ;

Yu Guoliang's layout of antibody drugs ;

Quanxin Biotechnology comprehensively sorted out ;

Anyuan Medical Technology is fully combed ;

Sansheng Guojian technology is fully combed ;

Renhui Biotechnology is comprehensively sorted out ;

Lepu Biotechnology is fully combed ;

Immune Onco's technology is all sorted out;

Paige Biotechnology is all sorted out;

Maiwei Biotechnology is all sorted out;

Momenta technology is fully combed ;

NGM technology is fully combed;

Purmis Biotechnology is fully combed ;

Clover biotechnology is fully combed ;

Betta Pharmaceuticals has sorted out all antibody drugs ;

Zejing Pharmaceutical's antibody drugs are fully combed ;

Hengrui Pharmaceutical's antibody drugs are fully combed ;

Qilu Pharmaceutical's antibody drugs are all sorted out;

CSPC antibody drugs are fully combed;

Hausen Pharmaceuticals comprehensively sorted out antibody drugs;

Huahai Pharmaceutical's antibody drugs are fully combed ;

Kelun Pharmaceutical's antibody drugs are all sorted out ;

Biotech's technology is fully combed ;

Fanenshi technology is all sorted out

Fanenshi technology is all sorted out
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.